481412
NF-kB Activation Inhibitor IV
The NF-kB Activation Inhibitor IV, also referenced under CAS 139141-12-1, controls the biological activity of NF-kB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
别名:
NF-kB Activation Inhibitor IV, (E)-2-Fluoro-4ʹ-methoxystilbene
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H13FO
化学文摘社编号:
分子量:
228.26
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
NF-kB Activation Inhibitor IV, The NF-kB Activation Inhibitor IV, also referenced under CAS 139141-12-1, controls the biological activity of NF-kB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
InChI key
ILVFNAZMSMNXJG-RMKNXTFCSA-N
SMILES string
Fc1c(cccc1)\C=C\c2ccc(cc2)OC
assay
≥98% (HPLC)
form
crystalline solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
solubility
DMSO: 20 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NF-κB Activation
NF-κB Activation
Product does not compete with ATP.
Reversible: no
Target IC50: 150 nM inhibiting TNF-α-stimulated NF-κB reporter activity in 293T cells.
Disclaimer
Toxicity: Standard Handling (A)
General description
A cell-permeable trans-stilbene Resveratrol (Cat. No. 554325) analog that exhibits much enhanced anti-inflammatory potency, but no anti-oxidant activity. Suppresses LPS-induced COX-2 mRNA expression in BV-2 cells (~46% inhibition at 150 nM) and Shown to be ~130-fold more potent than Resveratrol in inhibiting TNF-α-stimulated NF-κB reporter activity in 293T cells (IC50 = 150 nM).
Other Notes
Heynekamp, J.J., et al. 2006. J. Med. Chem.49, 7182.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Pascal Gelebart et al.
Translational oncology, 4(1), 9-19 (2011-02-03)
Mantle cell lymphoma (MCL) is a specific type of aggressive B-cell non-Hodgkin lymphoma. We recently found that IL-22RA1, one of the two subunits of the interleukin 22 (IL-22) receptor, is expressed in MCL cell lines but not benign lymphocytes. In
Yun-Ru Jaoying Huang et al.
Journal of cellular physiology, 237(12), 4517-4530 (2022-10-18)
Golgi apparatus (GA) and centrosome reposition toward cell leading end during directional cell migration in a coupling way, thereby determining cell polarity by transporting essential factors to the proximal plasma membrane. The study provides mechanistic insights into how GA repositioning
Je Sun Lim et al.
Cell death & disease, 13(11), 1002-1002 (2022-11-27)
Glioblastoma (GBM) is a highly vascular malignant brain tumor that overexpresses vascular endothelial growth factor (VEGF) and phosphofructokinase 1 platelet isoform (PFKP), which catalyzes a rate-limiting reaction in glycolysis. However, whether PFKP and VEGF are reciprocally regulated during GBM tumor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持